Andreou I, et al. - Ticagrelor's safety, as well as efficacy, was tested as an alternative to clopidogrel in patients on oral anticoagulation (OAC). Researchers searched MEDLINE, EMBASE, and the Cochrane Library to identify randomised controlled studies that assessed the relative safety and efficacy of clopidogrel vs ticagrelor among patients requiring therapy with antiplatelet agents plus OAC. The analysis of gathered data revealed that in comparison to clopidogrel, use of ticagrelor as part of dual or triple antithrombotic therapy was related to significantly higher rates of clinically relevant haemorrhagic complications. Consequent to the use of ticagrelor, an increase might be seen in the thromboembolic and ischaemic cardiac events among triple therapy-treated patients.